Shanghai Henlius Biotech Co. Ltd. and Shanghai Allist Pharmaceuticals Co., Ltd. led the group of Chinese biotech companies reporting full-year net profits in 2023, boosting confidence in the growing self-sustainability of domestic firms in the sector.
Key Takeaways
-
Three Chinese biotechs - Henlius, Akeso and Harbour Biomed - moved into the black for the first time in 2023.
Previously focused on biosimilars, Henlius last year reversed a money-losing streak to return an annual net profit of CNY546m, due...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

